CD8A and ovarian carcinoma: To investigate whether the reduced cross-processing of MVsMUC1 in X-DCs was still sufficient to activate MUC1 specific T cell responses, CD8+ T cells were isolated by immunomagnetic selection from PBMCs of an ovarian cancer patient, previously vaccinated with the HLAI-A2 restricted MUC1159−167 peptide (31).